Asztalos BF - Search Results

1

Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism.

Brousseau ME, Millar JS, Diffenderfer MR, Nartsupha C, Asztalos BF, Wolfe ML, Mancuso JP, Digenio AG, Rader DJ, Schaefer EJ. Brousseau ME, et al. Among authors: asztalos bf. J Lipid Res. 2009 Jul;50(7):1456-62. doi: 10.1194/jlr.P800037-JLR200. Epub 2009 Feb 3. J Lipid Res. 2009. PMID: 19193611 Free PMC article. Clinical Trial.

2

Differential response to low-fat diet between low and normal HDL-cholesterol subjects.

Asztalos B, Lefevre M, Wong L, Foster TA, Tulley R, Windhauser M, Zhang W, Roheim PS. Asztalos B, et al. J Lipid Res. 2000 Mar;41(3):321-8. J Lipid Res. 2000. PMID: 10706579 Free article. Clinical Trial.

3

Cellular cholesterol efflux in heterozygotes for tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size.

Brousseau ME, Eberhart GP, Dupuis J, Asztalos BF, Goldkamp AL, Schaefer EJ, Freeman MW. Brousseau ME, et al. Among authors: asztalos bf. J Lipid Res. 2000 Jul;41(7):1125-35. J Lipid Res. 2000. PMID: 10884295 Free article.

4

Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease.

Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, Schaefer EJ. Asztalos BF, et al. Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2670-6. doi: 10.1161/01.atv.20.12.2670. Arterioscler Thromb Vasc Biol. 2000. PMID: 11116070

5

Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease.

Asztalos BF, Brousseau ME, McNamara JR, Horvath KV, Roheim PS, Schaefer EJ. Asztalos BF, et al. Atherosclerosis. 2001 May;156(1):217-25. doi: 10.1016/s0021-9150(00)00643-2. Atherosclerosis. 2001. PMID: 11369017

6

Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients.

Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ. Asztalos BF, et al. Atherosclerosis. 2002 Oct;164(2):361-9. doi: 10.1016/s0021-9150(02)00149-1. Atherosclerosis. 2002. PMID: 12204809 Clinical Trial.

7

Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients.

Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ. Asztalos BF, et al. J Lipid Res. 2002 Oct;43(10):1701-7. doi: 10.1194/jlr.m200037-jlr200. J Lipid Res. 2002. PMID: 12364554 Free article. Clinical Trial.

8

Change in alpha1 HDL concentration predicts progression in coronary artery stenosis.

Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, Brown GB, Schaefer EJ. Asztalos BF, et al. Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):847-52. doi: 10.1161/01.ATV.0000066133.32063.BB. Epub 2003 Mar 13. Arterioscler Thromb Vasc Biol. 2003. PMID: 12637338 Clinical Trial.

9

High-density lipoprotein subpopulations in pathologic conditions.

Asztalos BF, Schaefer EJ. Asztalos BF, et al. Am J Cardiol. 2003 Apr 3;91(7A):12E-17E. doi: 10.1016/s0002-9149(02)03383-0. Am J Cardiol. 2003. PMID: 12679198 Review.

10

HDL in atherosclerosis: actor or bystander?

Asztalos BF, Schaefer EJ. Asztalos BF, et al. Atheroscler Suppl. 2003 Mar;4(1):21-9. doi: 10.1016/s1567-5688(03)00006-0. Atheroscler Suppl. 2003. PMID: 12714034 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

128 results

Search Page